• Home Dutch
  •  EN 
  • Employee login

Publications 2018

Print 
  1. Akkerman OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, de Vries G, Bolhuis MS, Alffenaar JW, Frijlink HW, Smith G, Gajraj R, de Zwaan R, Hagedoorn P, Dedicoat M, van Soolingen D, van der Werf TS. Cross border, highly individualized treatment of a patient with challenging extensively drug-resistant tuberculosis. Eur Respir J. 2018 Mar 22;51(3). pii: 1702490. doi: 10.1183/13993003.02490-2017. Print 2018 Mar. PubMed PMID: 29419442; PubMed Central PMCID: PMC5863047.
  2. Alffenaar JWC, Peloquin CA, Migliori GB. Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone. Int J Tuberc Lung Dis. 2018 Jan 1;22(1):2. doi: 10.5588/ijtld.17.0632. PubMed PMID: 29297417.
  3. Alfian SD, Worawutputtapong P, Schuiling-Veninga CCM, van der Schans J, Bos JHJ, Hak E, Denig P. Pharmacy-based predictors of non-persistence with and non-adherence to statin treatment among patients on oral diabetes medication in the Netherlands. Curr Med Res Opin. 2018 Jun;34(6):1013-1019. doi: 10.1080/03007995.2017.1417242. Epub 2018 Jan 15. PubMed PMID: 29292657.
  4. Apperloo EM, Pena MJ, de Zeeuw D, Denig P, Heerspink HJL. Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care  cohort study. Diabetes Obes Metab. 2018 Jun;20(6):1377-1383. doi: 10.1111/dom.13226. Epub 2018 Feb 20. PubMed PMID: 29345404; PubMed Central PMCID: PMC5969103.
  5. Bahar MA, Wang Y, Bos JHJ, Wilffert B, Hak E. Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly. Pharmacoepidemiol Drug Saf. 2018 Jun;27(6):621-629. doi: 10.1002/pds.4422. Epub 2018 Mar 24. PubMed PMID: 29575226; PubMed Central PMCID:  PMC6001522.
  6. Bakker SMK, Fenten MGE, Touw DJ, van den Bemt BJF, Heesterbeek PJC, Scheffer GJ, Stienstra R. Pharmacokinetics of 400 mg Locally Infiltrated Ropivacaine After Total Knee Arthroplasty Without Perioperative Tourniquet Use. Reg Anesth Pain Med. 2018 Oct;43(7):699-704. doi: 10.1097/AAP.0000000000000816. PubMed PMID: 29905628.
  7. Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, de Vries EGE, Schröder CP. (89)Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2300-2306. doi: 10.1007/s00259-018-4099-8. Epub 2018 Jul 30. PubMed PMID: 30058029; PubMed Central PMCID: PMC6208812.
  8. Bensch F, Smeenk MM, van Es SC, de Jong JR, Schröder CP, Oosting SF, Lub-de Hooge MN, Menke-van der Houven van Oordt CW, Brouwers AH, Boellaard R, de Vries EGE. Comparative biodistribution analysis across four different (89)Zr-monoclonal antibody tracers-The first step towards an imaging warehouse. Theranostics. 2018 Jul 30;8(16):4295-4304. doi: 10.7150/thno.26370. eCollection 2018. PubMed PMID: 30214621; PubMed Central PMCID: PMC6134927.
  9. Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, Groen HJM, Kwee TC, Elias SG, Gietema JA, Bohorquez SS, de Crespigny A, Williams SP, Mancao C, Brouwers AH, Fine BM, de Vries EGE. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018 Dec;24(12):1852-1858. doi: 10.1038/s41591-018-0255-8. Epub 2018 Nov 26. PubMed PMID: 30478423.
  10. Blind E, Janssen H, Dunder K, de Graeff PA. The European Medicines Agency's approval of new medicines for type 2 diabetes. Diabetes Obes Metab. 2018 Sep;20(9):2059-2063. doi: 10.1111/dom.13349. Epub 2018 May 30. Review. PubMed PMID: 29740935.
  11. Bolhuis MS, Akkerman OW, Sturkenboom MGG, Ghimire S, Srivastava S, Gumbo T, Alffenaar JC. Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment. Clin Infect Dis. 2018 Nov 28;67(suppl_3):S327-S335. doi: 10.1093/cid/ciy625. PubMed PMID: 30496467.
  12. Boonstra JM, Jongedijk EM, Koster RA, Touw DJ, Alffenaar JC. Simple and robust LC-MS/MS analysis method for therapeutic drug monitoring of micafungin. Bioanalysis. 2018 Jun 1;10(11):877-886. doi: 10.4155/bio-2017-0275. Epub 2018 Jun 4. PubMed PMID: 29863416.
  13. Bouma HR, Mungroop HE, de Geus AF, Huisman DD, Nijsten MWN, Mariani MA, Scheeren TWL, Burgerhof JGM, Henning RH, Epema AH. Acute Kidney Injury Classification Underestimates Long-Term Mortality After Cardiac Valve Operations. Ann Thorac Surg. 2018 Jul;106(1):92-98. doi: 10.1016/j.athoracsur.2018.01.066. Epub 2018 Mar 1. PubMed PMID: 29501641.
  14. Bouma HR, Mungroop HE, Henning RH, Epema AH. Reply. Ann Thorac Surg. 2018 Dec;106(6):1891-1892. doi: 10.1016/j.athoracsur.2018.07.006. Epub 2018 Aug 11. PubMed PMID: 30107141.
  15. Caño-Muñiz S, Anthony R, Niemann S, Alffenaar JC. New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State. Clin Microbiol Rev. 2017 Nov 29;31(1). pii: e00060-17. doi: 10.1128/CMR.00060-17. Print 2018 Jan. Review. PubMed PMID: 29187395; PubMed Central PMCID: PMC5740979.
  16. Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, Heerspink HJL, O'Grady M, Pergola PE, Wanner C, Warnock DG, Meyer CJ. Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. Am J Nephrol. 2018;47(1):40-47. doi: 10.1159/000486398. Epub 2018 Jan 18. PubMed PMID: 29402767; PubMed Central PMCID: PMC5841134.
  17. Chronic Kidney Disease Prognosis Consortium. Erratum: Evans M, Grams ME, Sang Y, et al., for the Chronic Kidney Disease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625-637. Kidney Int Rep. 2018 Aug 30;3(6):1506. doi: 10.1016/j.ekir.2018.08.009. eCollection 2018 Nov. PubMed PMID: 30450480; PubMed Central PMCID: PMC6224632.
  18. Cogut V, Bruintjes JJ, Eggen BJL, van der Zee EA, Henning RH. Brain inflammatory cytokines and microglia morphology changes throughout hibernation phases in Syrian hamster. Brain Behav Immun. 2018 Feb;68:17-22. doi: 10.1016/j.bbi.2017.10.009. Epub 2017 Oct 14. PubMed PMID: 29038037.
  19. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review. PubMed PMID: 30215381.
  20. Crowley, K, de Vries, ST & Moreno-Sanz, G 2018, 'Self-Reported Effectiveness and Safety of Trokie (R) Lozenges: A Standardized Formulation for the Buccal Delivery of Cannabis Extracts', Frontiers in Neuroscience, vol. 12, 564. https://doi.org/10.3389/fnins.2018.00564
  21. Cushen B, Sulaiman I, Greene G, MacHale E, Mokoka M, Reilly RB, Bennett K, Doyle F, van Boven JFM, Costello RW. The Clinical Impact of Different Adherence Behaviors in Patients with Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018 Jun 15;197(12):1630-1633. doi: 10.1164/rccm.201712-2469LE. PubMed PMID: 29351380.
  22. Daskapan A, Stienstra Y, Kosterink JGW, Bierman WFW, van der Werf TS, Touw DJ, Alffenaar JC. Risk factors contributing to a low darunavir plasma concentration.  Br J Clin Pharmacol. 2018 Mar;84(3):456-461. doi: 10.1111/bcp.13464. Epub 2017 Dec 7. PubMed PMID: 29077230; PubMed Central PMCID: PMC5809517.
  23. Daskapan, A, van Hateren, K, Stienstra, Y, Kosterink, J, van der Werf, T, Touw, D & Alffenaar, J-W 2018, 'Development and Validation of a Bioanalytical Method for the Simul- taneous Determination of 14 Antiretroviral Drugs using Liquid Chro- matography-Tandem Mass Spectrometry' Journal of Applied Bioanalysis, vol 4, no. 2, pp. 37-50. DOI: 10.17145/jab.18.007
  24. Davies Forsman L, Niward K, Hu Y, Zheng R, Zheng X, Ke R, Cai W, Hong C, Li Y, Gao Y, Werngren J, Paues J, Kuhlin J, Simonsson USH, Eliasson E, Alffenaar JW, Mansjö M, Hoffner S, Xu B, Schön T, Bruchfeld J. Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study. BMJ Open. 2018 Oct 4;8(9):e023899. doi: 10.1136/bmjopen-2018-023899. PubMed PMID: 30287613; PubMed Central PMCID: PMC6173237.
  25. de Vries JK, Balder JW, Pena MJ, Denig P, Smit AJ. Non-LDL dyslipidemia is prevalent in the young and determined by lifestyle factors and age: The LifeLines cohort. Atherosclerosis. 2018 Jul;274:191-198. doi: 10.1016/j.atherosclerosis.2018.05.016. Epub 2018 May 25. PubMed PMID: 29793176.
  26. de Vries ST, Denig P, Lasheras Ruiz C, Houÿez F, Wong L, Sutcliffe A, Mol PGM; IMI Web-RADR Work Package 3b Consortium. Interest in a Mobile App for Two-Way Risk Communication: A Survey Study Among European Healthcare Professionals and Patients. Drug Saf. 2018 Jul;41(7):697-712. doi: 10.1007/s40264-018-0648-0. PubMed PMID: 29500800; PubMed Central PMCID: PMC5990568.
  27. de Vries ST, van der Sar MJM, Coleman AM, Escudero Y, Rodríguez Pascual A, Maciá Martínez MÁ, Cupelli A, Baldelli I, Šipić I, Andrić A, Michan L, Denig P, Mol PGM; SCOPE work package 6. Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study. Drug Saf. 2018 Jul;41(7):713-724. doi: 10.1007/s40264-018-0643-5. PubMed PMID: 29500798; PubMed Central PMCID: PMC5990574.
  28. de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.Lancet Diabetes Endocrinol. 2018 Dec;6(12):925-933. doi: 10.1016/S2213-8587(18)30289-4. Epub 2018 Nov 6. PubMed PMID: 30413396.
  29. de Zeeuw, D, Heerspink, HJL, Jardine, M & Perkovic, V 2018, 'Renal trials in diabetes need a platform: time for a global approach?' Lancet Diabetes & Endocrinology, vol 6, no. 5, pp. 356-+. DOI: 10.1016/S2213-8587(17)30263-2
  30. Dekhuijzen R, Lavorini F, Usmani OS, van Boven JFM. Addressing the Impact and Unmet Needs of Nonadherence in Asthma and Chronic Obstructive Pulmonary Disease: Where Do We Go From Here? J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):785-793. doi: 10.1016/j.jaip.2017.11.027. Epub 2018 Jan 12. PubMed PMID: 29339126.
  31. Dekkers BGJ, Veringa A, Marriott DJE, Boonstra JM, van der Elst KCM, Doukas FF, McLachlan AJ, Alffenaar JC. Invasive Candidiasis in the Elderly: Considerations for Drug Therapy. Drugs Aging. 2018 Sep;35(9):781-789. doi: 10.1007/s40266-018-0576-9. PubMed PMID: 30047069; PubMed Central PMCID:PMC6105183.
  32. Dekkers CCJ, Gansevoort RT, Heerspink HJL. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Curr Diab Rep. 2018 Mar 27;18(5):27. doi: 10.1007/s11892-018-0992-6. Review. PubMed PMID: 29589183.
  33. Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018 Aug;20(8):1988-1993. doi: 10.1111/dom.13301. Epub 2018 Apr 23. PubMed PMID: 29573529.
  34. Dekkers CCJ, Wheeler DC, Sjöström CD, Stefansson BV, Cain V, Heerspink HJL. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. Nephrol Dial Transplant. 2018 Jul 1;33(7):1280. doi: 10.1093/ndt/gfy135. PubMed PMID 29762740; PubMed Central PMCID: PMC6031052.
  35. Deshpande D, Alffenaar JC, Köser CU, Dheda K, Chapagain ML, Simbar N, Schön T, Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S, Ogarkov O, Pholwat S, Houpt ER, Heysell SK, Gumbo T. d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624. PubMed PMID: 30496460; PubMed Central PMCID: PMC6260153
  36. Dijkstra JA, van der Laan T, Akkerman OW, Bolhuis MS, de Lange WCM, Kosterink JGW, van der Werf TS, Alffenaar JWC, van Soolingen D. In Vitro Susceptibility of  Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin. Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01724-17. doi: 10.1128/AAC.01724-17. Print 2018 Mar. PubMed PMID: 29311078; PubMed Central PMCID: PMC5826127.
  37. Doestzada M, Vila AV, Zhernakova A, Koonen DPY, Weersma RK, Touw DJ, Kuipers  F, Wijmenga C, Fu J. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell. 2018 May;9(5):432-445. doi: 10.1007/s13238-018-0547-2. Epub 2018 Apr 28. Review. PubMed PMID: 29705929; PubMed Central PMCID:PMC5960471.
  38. Dugbartey, GJ, Bouma, HR, Saha, MN, Lobb, I, Henning, RH & Sener, A 2018, 'A Hibernation-Like State for Transplantable Organs: Is Hydrogen Sulfide Therapy the Future of Organ Preservation?' Antioxidants & Redox Signaling, vol 28, no. 16, pp. 1503-1515. DOI: 10.1089/ars.2017.7127
  39. Eckardt KU, Bansal N, Coresh J, Evans M, Grams ME, Herzog CA, James MT, Heerspink HJL, Pollock CA, Stevens PE, Tamura MK, Tonelli MA, Wheeler DC, Winkelmayer WC, Cheung M, Hemmelgarn BR; Conference Participants. Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2018 Jun;93(6):1281-1292. doi: 10.1016/j.kint.2018.02.006. Epub 2018 Apr 12. PubMed PMID: 29656903; PubMed Central PMCID: PMC5998808.
  40. Eder S, Leierer J, Kerschbaum J, Rosivall L, Wiecek A, de Zeeuw D, Mark PB, Heinze G, Rossing P, Heerspink HL, Mayer G. A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics. Kidney Blood Press Res. 2018;43(1):181-190. doi: 10.1159/000487500. Epub 2018 Feb 16. PubMed PMID:29466797.
  41. Eisenga MF, Kieneker LM, Touw DJ, Nolte IM, van der Meer P, Huls G, Gaillard CAJM, Bakker SJL. Active Smoking and Hematocrit and Fasting Circulating Erythropoietin Concentrations in the General Population. Mayo Clin Proc. 2018 Mar;93(3):337-343. doi: 10.1016/j.mayocp.2018.01.005. PubMed PMID: 29502563.
  42. Ekhart, C, van Hunsel, F, Scholl, J, de Vries, S & van Puijenbroek, E 2018, 'Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors', Drug Safety, vol. 41, no. 7, pp. 677-683. https://doi.org/(...)07/s40264-018-0646-2
  43. GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet. 2018 Jun 2;391(10136):2236-2271. doi: 10.1016/S0140-6736(18)30994-2. Epub 2018 Jun 1. PubMed PMID: 29893224; PubMed Central PMCID: PMC5986687.
  44. Global Burden of Disease 2016 Greece Collaborators. The burden of disease in Greece, health loss, risk factors, and health financing, 2000-16: an analysis of  the Global Burden of Disease Study 2016. Lancet Public Health. 2018 Aug;3(8):e395-e406. doi: 10.1016/S2468-2667(18)30130-0. Epub 2018 Jul 25. PubMed  PMID: 30055996; PubMed Central PMCID: PMC6079016.
  45. Grams ME, Sang Y, Ballew SH, Carrero JJ, Djurdjev O, Heerspink HJL, Ho K, Ito S, Marks A, Naimark D, Nash DM, Navaneethan SD, Sarnak M, Stengel B, Visseren FLJ, Wang AY, Köttgen A, Levey AS, Woodward M, Eckardt KU, Hemmelgarn B, Coresh J. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 2018 Jun;93(6):1442-1451. doi: 10.1016/j.kint.2018.01.009. Epub 2018 Mar 29. PubMed PMID: 29605094; PubMed Central PMCID: PMC5967981.
  46. Gumbo T, Alffenaar JC. Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs. Clin Infect Dis. 2018 Nov 28;67(suppl_3):S267-S273. doi: 10.1093/cid/ciy608. PubMed PMID: 30496455; PubMed Central PMCID: PMC6260166.
  47. Hartmans E, Tjalma JJJ, Linssen MD, Allende PBG, Koller M, Jorritsma-Smit A, Nery MESO, Elias SG, Karrenbeld A, de Vries EGE, Kleibeuker JH, van Dam GM, Robinson DJ, Ntziachristos V, Nagengast WB. Potential Red-Flag Identification of  Colorectal Adenomas with Wide-Field Fluorescence Molecular Endoscopy. Theranostics. 2018 Feb 5;8(6):1458-1467. doi: 10.7150/thno.22033. eCollection 2018. PubMed PMID: 29556334; PubMed Central PMCID: PMC5858160.
  48. Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Yi T, Parving HH, de Zeeuw D. Baseline characteristics and enrichment results from the  SONAR trial. Diabetes Obes Metab. 2018 Aug;20(8):1829-1835. doi: 10.1111/dom.13315. Epub 2018 May 1. PubMed PMID: 29604160.
  49. Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Dey J, Hou  FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 Jun;20(6):1369-1376. doi: 10.1111/dom.13245. Epub 2018 Mar 9. PubMed PMID: 29405626; PubMed Central PMCID:  PMC5969254.
  50. Heerspink HJL, de Zeeuw D. Treating diabetic complications; from large randomized clinical trials to precision medicine. Diabetes Obes Metab. 2018 Oct;20 Suppl 3:3-5. doi: 10.1111/dom.13418. Review. PubMed PMID: 30294952; PubMed Central PMCID: PMC6221145.
  51. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018 Jul;94(1):26-39. doi: 10.1016/j.kint.2017.12.027. Epub 2018 May 5. Review. PubMed PMID: 29735306.
  52. Heerspink HJL, List J, Perkovic V. New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. Diabetes Obes Metab. 2018 Oct;20 Suppl 3:14-18. doi: 10.1111/dom.13417. Review. PubMed PMID: 30294954; PubMed Central PMCID: PMC6220936.
  53. Heerspink HJL, Perkovic V. Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform. Clin J Am Soc Nephrol. 2018 Jun 7;13(6):946-948. doi: 10.2215/CJN.01290118. Epub 2018 Apr 26. PubMed PMID: 29700075; PubMed Central PMCID: PMC5989668.
  54. Hendriks KDW, Lupi E, Hardenberg MC, Hoogstra-Berends F, Deelman LE, Henning RH. Differences in mitochondrial function and morphology during cooling and rewarming between hibernator and non-hibernator derived kidney epithelial cells.  Sci Rep. 2017 Nov 14;7(1):15482. doi: 10.1038/s41598-017-15606-z. PubMed PMID: 29138454; PubMed Central PMCID: PMC5686174.
  55. Henning RH, Brundel BJJM. Proteostasis in cardiac health and disease. Nat Rev  Cardiol. 2017 Nov;14(11):637-653. doi: 10.1038/nrcardio.2017.89. Epub 2017 Jun 29. Review. PubMed PMID: 28660894.
  56. Huang Y, Jiang Y, Zhang L, Mao W, van Boven JFM, Postma MJ, Chen W. Availability, use, and affordability of medicines in urban China under universal  health coverage: an empirical study in Hangzhou and Baoji. BMC Health Serv Res. 2018 Mar 27;18(1):218. doi: 10.1186/s12913-018-2993-1. PubMed PMID: 29587742.
  57. Hurst JR, Dickhaus J, Maulik PK, Miranda JJ, Pastakia SD, Soriano JB, Siddharthan T, Vedanthan R; GACD Multi-Morbidity Working Group. Global Alliance for Chronic Disease researchers' statement on multimorbidity. Lancet Glob Health. 2018 Dec;6(12):e1270-e1271. doi: 10.1016/S2214-109X(18)30391-7. PubMed PMID: 30420026.
  58. Idzerda NMA, Pena MJ, Heerspink HJL. Personalized medicine in diabetic kidney disease: a novel approach to improve trial design and patient outcomes. Curr Opin Nephrol Hypertens. 2018 Nov;27(6):426-432. doi: 10.1097/MNH.0000000000000447. PubMed PMID: 30095480.
  59. Idzerda NMA, Persson F, Pena MJ, Brenner BM, Brunel P, Chaturvedi N, McMurray JJ, Parving HH, de Zeeuw D, Heerspink HJL. N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. Diabetes Obes Metab. 2018 Dec;20(12):2899-2904. doi: 10.1111/dom.13465. Epub 2018 Aug 5. PubMed PMID:  29987919.
  60. Ivanova SA, Alifirova VM, Pozhidaev IV, Freidin MB, Zhukova IA, Osmanova DZ, Zhukova NG, Mironova YA, Tiguntsev VV, Fedorenko OY, Bokhan NA, Wilffert B, Loonen AJM. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia. J Pharm Pharm Sci. 2018;21(1):340-346. doi: 10.18433/jpps29903. PubMed PMID: 30075828.
  61. Jansen BHE, Disselhorst GW, Schutte T, Jansen B, Rissmann R, Richir MC, Keijsers CJPW, Vanmolkot FHM, van den Brink AM, Kramers C, Vondeling AM, Dumont GJH, de Waard-Siebinga I, Van Agtmael MA, Tichelaar J. Essential diseases in prescribing: A national Delphi study towards a core curriculum in pharmacotherapy education. Br J Clin Pharmacol. 2018 Nov;84(11):2645-2650. doi: 10.1111/bcp.13730. Epub 2018 Sep 6. PubMed PMID: 30076631; PubMed Central PMCID: PMC6177701.
  62. Jonker CJ, Kwa MSG, van den Berg HM, Hoes AW, Mol PGM. Drug Registries and Approval of Drugs: Promises, Placebo, or a Real Success? Clin Ther. 2018 May;40(5):768-773. doi: 10.1016/j.clinthera.2018.04.005. Epub 2018 Apr 27. PubMed PMID: 29709456.
  63. Juárez-Orozco, LE, Alexanderson, E, Dierckx, RA, Boersma, HH, Hillege, JL, Zeebregts, CJ, Martínez-Aguilar, MM, Jordán-Ríos, A, Ayala-German, AG, Prakken, N, Tio, RA & Slart, RH 2018, 'Stress myocardial blood flow correlates with ventricular function and synchrony better than myocardial perfusion reserve: A Nitrogen-13 ammonia PET study' Journal of Nuclear Cardiology, vol 25, no. 3, pp. 797-806. DOI: 10.1007/s12350-016-0669-y.
  64. Kim CH, Dilokthornsakul P, Campbell JD, van Boven JFM. Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating  Value? J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):619-632. doi: 10.1016/j.jaip.2017.07.028. Epub 2017 Sep 28. PubMed PMID: 28967548.
  65. Koller M, Qiu SQ, Linssen MD, Jansen L, Kelder W, de Vries J, Kruithof I, Zhang GJ, Robinson DJ, Nagengast WB, Jorritsma-Smit A, van der Vegt B, van Dam GM. Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers. Nat Commun. 2018 Sep 18;9(1):3739. doi: 10.1038/s41467-018-05727-y. PubMed PMID: 30228269; PubMed Central PMCID: PMC6143516.
  66. Koomen JV, Stevens J, Mostafa NM, Parving HH, de Zeeuw D, Heerspink HJL. Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight. Diabetes Obes Metab. 2018 Aug;20(8):2019-2022. doi: 10.1111/dom.13312. Epub 2018 May 1. PubMed PMID: 29603851.
  67. Koudijs KKM, Terwisscha van Scheltinga AGT, Böhringer S, Schimmel KJM, Guchelaar HJ. Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression. Sci Rep. 2018 Mar 27;8(1):5250. doi: 10.1038/s41598-018-23195-8. PubMed PMID: 29588458.
  68. Kovesdy CP, Matsushita K, Sang Y, Brunskill NJ, Carrero JJ, Chodick G, Hasegawa T, Heerspink HL, Hirayama A, Landman GWD, Levin A, Nitsch D, Wheeler DC, Coresh J, Hallan SI, Shalev V, Grams ME; CKD Prognosis Consortium . Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018 May 1;39(17):1535-1542. doi: 10.1093/eurheartj/ehy100. PubMed PMID: 29554312; PubMed Central PMCID: PMC5930249.
  69. Kroon MAGM, Akkerman-Nijland AM, Rottier BL, Koppelman GH, Akkerman OW, Touw DJ. Drugs during pregnancy and breast feeding in women diagnosed with Cystic Fibrosis - An update. J Cyst Fibros. 2018 Jan;17(1):17-25. doi: 10.1016/j.jcf.2017.11.009. Epub 2017 Dec 7. PubMed PMID: 29233472.
  70. Kuizenga MH, Colin PJ, Reyntjens KMEM, Touw DJ, Nalbat H, Knotnerus FH, Vereecke HEM, Struys MMRF. Test of neural inertia in humans during general anaesthesia. Br J Anaesth. 2018 Mar;120(3):525-536. doi: 10.1016/j.bja.2017.11.072. Epub 2017 Dec 1. PubMed PMID: 29452809.
  71. Kunutsor SK, Spee JM, Kieneker LM, Gansevoort RT, Dullaart RPF, Voerman AJ, Touw DJ, Bakker SJL. Self-Reported Smoking, Urine Cotinine, and Risk of Cardiovascular Disease: Findings From the PREVEND (Prevention of Renal and Vascular End-Stage Disease) Prospective Cohort Study. J Am Heart Assoc. 2018 May  2;7(10). pii: e008726. doi: 10.1161/JAHA.118.008726. PubMed PMID: 29720504; PubMed Central PMCID: PMC6015309.
  72. Levchenko A, Losenkov IS, Vyalova NM, Simutkin GG, Bokhan NA, Wilffert B, Loonen AJ, Ivanova SA. The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders. Pharmgenomics Pers Med. 2018 Jul 20;11:121-126. doi: 10.2147/PGPM.S171423. eCollection 2018. PubMed PMID: 30050316; PubMed Central PMCID: PMC6055890
  73. Lindhardt M, Persson F, Oxlund C, Jacobsen IA, Zürbig P, Mischak H, Rossing P, Heerspink HJL. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. Nephrol Dial Transplant. 2018 Feb 1;33(2):296-303. doi: 10.1093/ndt/gfw406. PubMed PMID: 28064163.
  74. Magis-Escurra C, Anthony RM, van der Zanden AGM, van Soolingen D, Alffenaar JC. Pound foolish and penny wise-when will dosing of rifampicin be optimised? Lancet Respir Med. 2018 Apr;6(4):e11-e12. doi: 10.1016/S2213-2600(18)30044-4. Epub 2018 Jan 29. PubMed PMID: 29396032.
  75. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018 Jan 23;137(4):323-334. doi: 10.1161/CIRCULATIONAHA.117.032038. Epub 2017 Nov 13. PubMed PMID: 29133604; PubMed Central PMCID: PMC5777572.
  76. Martial LC, Kerkhoff J, Martinez N, Rodríguez M, Coronel R, Molinas G, Roman M, Gomez R, Aguirre S, Jongedijk E, Huisman J, Touw DJ, Pérez D, Chaparro G, Gonzalez F, Aarnoutse RE, Alffenaar JW, Magis-Escurra C. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring  of anti-tuberculosis drugs in children. Int J Antimicrob Agents. 2018 Jul;52(1):109-113. doi: 10.1016/j.ijantimicag.2018.04.020. Epub 2018 May 8. PubMed PMID: 29751121.
  77. Mieras LF, Taal AT, van Brakel WH, Cambau E, Saunderson PR, Smith WCS, Prakoeswa CRS, Astari L, Scollard DM, do Nascimento DC, Grosset J, Kar HK, Izumi S, Gillini L, Virmond MCL, Sturkenboom MGG. An enhanced regimen as post-exposure  chemoprophylaxis for leprosy: PEP+. BMC Infect Dis. 2018 Oct 5;18(1):506. doi: 10.1186/s12879-018-3402-4. PubMed PMID: 30290790; PubMed Central PMCID: PMC6173927.
  78. Mol PGM, Thompson A, Heerspink HJL, Leufkens HGM. Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations. Diabetes Obes Metab. 2018 Oct;20 Suppl 3:19-23. doi: 10.1111/dom.13453. Review. PubMed PMID: 30294953; PubMed Central PMCID: PMC6220800.
  79. Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL, van Raalte DH. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018 Nov;6(11):859-869. doi: 10.1016/S2213-8587(18)30268-7. Epub 2018 Oct 3. PubMed PMID: 30292589.
  80. Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 Oct 9;138(15):1537-1550. doi: 10.1161/CIRCULATIONAHA.118.035901. PubMed PMID: 29941478; PubMed Central PMCID: PMC6181277.
  81. Ortiz Zacarías NV, Dijkmans AC, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, Touw DJ, Kamerling IMC, Stevens J. Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens. Pharmacol Res Perspect. 2018 Feb;6(1). doi: 10.1002/prp2.378. PubMed PMID: 29417760; PubMed Central PMCID: PMC5803932.
  82. Pastrana, FR, Thompson, JM, Heuker, M, Hoekstra, H, Dillen, CA, Ortines, RV, Ashbaugh, AG, Pickett, JE, Linssen, MD, Bernthal, NM, Francis, KP, Buist, G, van Oosten, M, van Dam, GM, Thorek, DLJ, Miller, LS & van Dijl, JM 2018, 'Noninvasive optical and nuclear imaging of Staphylococcus-specific infection with a human monoclonal antibody-based probe' Virulence, vol 9, no. 1, pp. 262-272. DOI: 10.1080/21505594.2017.1403004
  83. Perco P, Pena M, Heerspink HJL, Mayer G; BEAt-DKD Consortium. Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice? Kidney Int Rep. 2018 Dec 18;4(2):212-221. doi: 10.1016/j.ekir.2018.12.001. eCollection 2019 Feb. Review. PubMed PMID: 30775618; PubMed Central PMCID: PMC6365367.
  84. Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21. PubMed PMID: 29937267
  85. Perwitasari DA, Darmawan E, Mulyani UA, Vlies PV, Alffenaar JC, Atthobar J, Wilffert B. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients. Int J Mycobacteriol. 2018 Oct-Dec;7(4):380-386. doi: 10.4103/ijmy.ijmy_143_18. PubMed PMID: 30531039.
  86. Petrykiv S, Laverman GD, de Zeeuw D, Heerspink HJL. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition? Diabetes Obes Metab. 2018 Jan;20(1):224-227. doi: 10.1111/dom.13057. Epub 2017 Aug 8. PubMed PMID: 28685934.
  87. Pieterman ED, Te Brake LHM, de Knegt GJ, van der Meijden A, Alffenaar JC, Bax  HI, Aarnoutse RE, de Steenwinkel JEM. Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model. Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01354-18. doi: 10.1128/AAC.01354-18. Print 2018 Sep. PubMed PMID: 29987154
  88. Post, TE, Kamerling, IMC, van Rossen, RCJM, Burggraaf, J, Stevens, J, Dijkmans, AC, Heijerman, HGM, Touw, DJ, van Velzen, AJ & Wilms, EB 2018, 'Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration' European Journal of Hospital Pharmacy: Science and Practice, vol 25, no. 6, pp. 337-339. DOI: 10.1136/ejhpharm-2016-001128
  89. Provenzano M, Minutolo R, Chiodini P, Bellizzi V, Nappi F, Russo D, Borrelli S, Garofalo C, Iodice C, De Stefano T, Conte G, Heerspink HJL, De Nicola L. Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care. J Clin Med. 2018 Dec 1;7(12). pii: E499. doi: 10.3390/jcm7120499. PubMed PMID: 30513744.
  90. Robijns K, van Luin M, Jansen RTP, Neef C, Touw DJ. A design for external quality assessment for the analysis of thiopurine drugs: pitfalls and opportunities. Clin Chem Lab Med. 2018 Sep 25;56(10):1715-1721. doi: 10.1515/cclm-2018-0116. PubMed PMID: 30110249.
  91. Romero Pastrana F, Thompson JM, Heuker M, Hoekstra H, Dillen CA, Ortines RV, Ashbaugh AG, Pickett JE, Linssen MD, Bernthal NM, Francis KP, Buist G, van Oosten M, van Dam GM, Thorek DLJ, Miller LS, van Dijl JM. Noninvasive optical and nuclear imaging of Staphylococcus-specific infection with a human monoclonal antibody-based probe. Virulence. 2018 Jan 1;9(1):262-272. doi: 10.1080/21505594.2017.1403004. Epub 2017 Dec 26. PubMed PMID: 29166841; PubMed Central PMCID: PMC5955194.
  92. Savonitto S, Morici N, Nozza A, Cosentino F, Perrone Filardi P, Murena E, Morocutti G, Ferri M, Cavallini C, Eijkemans MJ, Stähli BE, Schrieks IC, Toyama T, Lambers Heerspink HJ, Malmberg K, Schwartz GG, Lincoff AM, Ryden L, Tardif JC, Grobbee DE. Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. Diab Vasc Dis Res. 2018 Jan;15(1):14-23. doi: 10.1177/1479164117735493. Epub 2017 Oct 20. PubMed PMID: 29052439.
  93. SCOPE Work Package 6 2018, 'Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study', Drug Safety, vol. 41, no. 7, pp. 713-724. https://doi.org/(...)07/s40264-018-0643-5
  94. Sediq R, van der Schans J, Dotinga A, Alingh RA, Wilffert B, Bos JH, Schuiling-Veninga CC, Hak E. Concordance assessment of self-reported medication use in the Netherlands three-generation Lifelines Cohort study with the pharmacy  database iaDB.nl: The PharmLines initiative. Clin Epidemiol. 2018 Aug 16;10:981-989. doi: 10.2147/CLEP.S163037. eCollection 2018. PubMed PMID: 30147377; PubMed Central PMCID: PMC6101003
  95. Seferovic JP, Pfeffer MA, Claggett B, Desai AS, de Zeeuw D, Haffner SM, McMurray JJV, Parving HH, Solomon SD, Chaturvedi N. Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information  on cardiovascular outcomes: analysis of ALTITUDE trial. Diabetologia. 2018 Mar;61(3):581-588. doi: 10.1007/s00125-017-4485-y. Epub 2017 Nov 3. PubMed PMID:  29098323.
  96. Sidorenkov G, van Boven JFM, Hoekstra T, Nijpels G, Hoogenberg K, Denig P. HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups. Diabetes Obes Metab. 2018  Aug;20(8):1957-1964. doi: 10.1111/dom.13332. Epub 2018 May 24. PubMed PMID: 29687577.
  97. Silva DR, Rendon A, Alffenaar JW, Chakaya JM, Sotgiu G, Esposito S, Migliori GB. Global TB Network: working together to eliminate tuberculosis. J Bras Pneumol. 2018 Set-Oct;44(5):347-349. doi: 10.1590/S1806-37562018000000279. English, Portuguese. PubMed PMID: 30304206.
  98. Smith MY, Russell A, Bahri P, Mol PGM, Frise S, Freeman E, Morrato EH. The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products. Drug Saf. 2018 Apr;41(4):389-401. doi: 10.1007/s40264-017-0619-x. PubMed PMID: 29218682; PubMed Central PMCID: PMC5878197.
  99. Smits KPJ, Sidorenkov G, Kleefstra N, Hendriks SH, Bouma M, Meulepas M, Navis  G, Bilo HJG, Denig P. Is guideline-adherent prescribing associated with quality of life in patients with type 2 diabetes? PLoS One. 2018 Aug 16;13(8):e0202319. doi: 10.1371/journal.pone.0202319. eCollection 2018. PubMed PMID: 30114242; PubMed Central PMCID: PMC6095535.
  100. Sotomayor CG, Gomes-Neto AW, Gans ROB, de Borst MH, Berger SP, Rodrigo R, Navis GJ, Touw DJ, Bakker SJL. Fish Intake, Circulating Mercury and Mortality in Renal Transplant Recipients. Nutrients. 2018 Oct 3;10(10). pii: E1419. doi: 10.3390/nu10101419. PubMed PMID: 30282924; PubMed Central PMCID: PMC6212909.
  101. Stolmeijer R, Bouma HR, Zijlstra JG, Drost-de Klerck AM, Ter Maaten JC, Ligtenberg JJM. A Systematic Review of the Effects of Hyperoxia in Acutely Ill Patients: Should We Aim for Less? Biomed Res Int. 2018 May 14;2018:7841295. doi: 10.1155/2018/7841295. eCollection 2018. Review. PubMed PMID: 29888278; PubMed Central PMCID: PMC5977014.
  102. Storey BC, Staplin N, Haynes R, Reith C, Emberson J, Herrington WG, Wheeler DC, Walker R, Fellström B, Wanner C, Landray MJ, Baigent C; SHARP Collaborative Group. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney Int. 2018 Apr;93(4):1000-1007. doi: 10.1016/j.kint.2017.09.011. Epub 2017 Nov 14. PubMed PMID: 29146277.
  103. Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, Requena-Méndez A, Peloquin C, Koegelenberg CFN, Alffenaar JWC, Ruslami R, Tostmann A, Swaminathan S, McIlleron H, Davies G. Pharmacokinetics of rifampicin  in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother. 2018 Sep 1;73(9):2305-2313. doi: 10.1093/jac/dky152. PubMed PMID: 29701775; PubMed Central PMCID: PMC6105874.
  104. Sturkenboom MGG, Simbar N, Akkerman OW, Ghimire S, Bolhuis MS, Alffenaar JC. Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise  the Current Recommended Dose for Tuberculosis Treatment. Clin Infect Dis. 2018 Nov 28;67(suppl_3):S303-S307. doi: 10.1093/cid/ciy613. PubMed PMID: 30496466.
  105. Suthahar N, Meijers WC, Brouwers FP, Heerspink HJL, Gansevoort RT, van der Harst P, Bakker SJL, de Boer RA. Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population. Int J Cardiol. 2018 Jan 1;250:188-194. doi: 10.1016/j.ijcard.2017.10.035. Epub 2017 Oct 16. PubMed PMID: 29074040.
  106. Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk AM, Houwink EJF,  Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Guchelaar HJ; Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP). Pharmacogenetic Information in Clinical Guidelines: The European Perspective. Clin Pharmacol Ther. 2018 May;103(5):795-801. doi: 10.1002/cpt.1049. Epub 2018 Mar 30. Review. PubMed PMID: 29460273.
  107. Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Centis R, Alffenaar JW, Migliori GB. Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis. Eur Respir J. 2018 Mar 22;51(3). pii: 1702187. doi: 10.1183/13993003.02187-2017. Print 2018 Mar. PubMed PMID: 29567720.
  108. Toshchakova, VA, Bakhtiari, Y, Kulikov, AV, Gusev, SI, Trofimova, MV, Fedorenko, OY, Mikhalitskaya, EV, Popova, NK, Bokhan, NA, Hovens, JE, Loonen, AJM, Wilffert, B & Ivanova, SA 2018, 'Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders' Neuropsychobiology, vol 75, no. 4, pp. 200-210. DOI: 10.1159/000487484
  109. van Boven JFM, Cushen B, Sulaiman I, Greene G, MacHale E, Mokoka MC, Doyle F,  Reilly RB, Bennett K, Costello RW. Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis. NPJ Prim Care Respir Med. 2018 Jun 27;28(1):24. doi: 10.1038/s41533-018-0092-8. PubMed PMID: 29950601; PubMed Central PMCID: PMC6021429.
  110. van den Belt SM, Gracchi V, de Zeeuw D, Heerspink HJL. How to measure and monitor albuminuria in healthy toddlers? PLoS One. 2018 Jun 21;13(6):e0199309. doi: 10.1371/journal.pone.0199309. eCollection 2018. PubMed PMID: 29927975; PubMed Central PMCID: PMC6013108.
  111. van den Belt SM, Heerspink HJL, Gracchi V, de Zeeuw D, Wühl E, Schaefer F; ESCAPE Trial Group. Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD. J Am Soc Nephrol. 2018 Aug;29(8):2225-2233. doi: 10.1681/ASN.2018010036. Epub 2018 Jun 21. PubMed PMID: 29930161; PubMed Central PMCID: PMC6065076.
  112. van den Elsen SHJ, Akkerman OW, Huisman JR, Touw DJ, van der Werf TS, Bolhuis MS, Alffenaar JC. Lack of penetration of amikacin into saliva of tuberculosis patients. Eur Respir J. 2018 Jan 11;51(1). pii: 1702024. doi: 10.1183/13993003.02024-2017. Print 2018 Jan. PubMed PMID: 29326320.
  113. van den Elsen SHJ, Oostenbrink LM, Heysell SK, Hira D, Touw DJ, Akkerman OW,  Bolhuis MS, Alffenaar JC. Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring. Ther Drug Monit. 2018 Feb;40(1):17-37. doi: 10.1097/FTD.0000000000000462. PubMed PMID: 29120971.
  114. van den Elsen SHJ, Sturkenboom MGG, Van't Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK, Mpagama S, Migliori GB, Peloquin CA, Touw DJ, Alffenaar JC. Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01092-18. doi: 10.1128/AAC.01092-18. Print 2018 Dec. PubMed PMID: 30373800.
  115. van der Veen EL, Bensch F, Glaudemans AWJM, Lub-de Hooge MN, de Vries EGE. Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. Cancer Treat Rev. 2018 Nov;70:232-244. doi: 10.1016/j.ctrv.2018.09.007. Epub 2018 Sep 25. Review. PubMed PMID: 30308466.
  116. van Esdonk MJ, Lindeman I, Okkerse P, de Kam ML, Groeneveld GJ, Stevens J. Population pharmacokinetic/pharmacodynamic analysis of nociceptive pain models following an oral pregabalin dose administration to healthy subjects. CPT: Pharmacometrics & Systems Pharmacology. 2018 Sep;7(9):573-580. Available from, DOI: 10.1002/psp4.12318.
  117. van Esdonk MJ, Stevens J, van der Graaf PH, Burggraaf J. A Deconvolution Informed Pharmacodynamic Model For The Quantification Of Drug Effects On Highly Pulsatile Endogenous Profiles. Clinical Pharmacology & Therapeutics. 2018 Mar;103:S11.
  118. van Esdonk MJ, van Zutphen EJM, Roelfsema F, Pereira AM, van der Graaf PH, Biermasz NR, Stevens J, Burggraaf J. How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary. 2018 Jun;21(3):310-322. doi: 10.1007/s11102-018-0884-4. Review. PubMed PMID: 29605877; PubMed Central PMCID: PMC5942341.
  119. Vanbrabant TJF, Dijkmans AC, den Hartigh J, Touw DJ, Arend SM. Rifampin levels in daily practice: the accuracy of a single measurement. Neth J Med. 2018 Jul;76(5):235-242. PubMed PMID: 30019679.
  120. Verschueren MV, Jansman FGA, Touw DJ, Kramers C. [Treating poisoning; how do you choose the best type of gastrointestinal decontamination?]. Ned Tijdschr Geneeskd. 2018;162(0):D1574. Dutch. PubMed PMID: 29350117.
  121. Voorham J, Roche N, Benhaddi H, van der Tol M, Carter V, van Boven JFM, Bjermer L, Miravitlles M, Price DB. Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK. BMJ Open. 2018 Oct 27;8(10):e022051. doi: 10.1136/bmjopen-2018-022051. PubMed PMID: 30368448.
  122. Waaijer SJH, Kok IC, Eisses B, Schröder CP, Jalving M, Brouwers AH, Lub-de Hooge MN, de Vries EGE. Molecular Imaging in Cancer Drug Development. J Nucl Med. 2018 May;59(5):726-732. doi: 10.2967/jnumed.116.188045. Epub 2018 Jan 25. PubMed  PMID: 29371402.
  123. Waaijer SJH, Warnders FJ, Stienen S, Friedrich M, Sternjak A, Cheung HK, van Scheltinga AGTT, Schröder CP, de Vries EGE, Lub-de Hooge MN. Molecular Imaging of Radiolabeled Bispecific T-Cell Engager (89)Zr-AMG211 Targeting CEA-Positive Tumors. Clin Cancer Res. 2018 Oct 15;24(20):4988-4996. doi: 10.1158/1078-0432.CCR-18-0786. Epub 2018 Jul 6. PubMed PMID: 29980531; PubMed Central PMCID: PMC6193542.
  124. Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12. PubMed PMID: 30314978; PubMed Central PMCID: PMC6218863.
  125. Warnders FJ, Lub-de Hooge MN, de Vries EGE, Kosterink JGW. Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non-Ig scaffolds. Med Res Rev. 2018 Sep;38(6):1837-1873. doi: 10.1002/med.21498. Epub 2018 Apr 10. Review. PubMed PMID: 29635825.
  126. Weersink, RA, Bouma, M, Burger, DM, Drenth, JPH, Froukje Harkes-Idzinga, S, Hunfeld, NGM, Metselaar, HJ, Monster-Simons, MH, van Putten, SAW, Taxis, K & Borgsteede, SD 2018, 'Safe use of proton pump inhibitors in patients with cirrhosis', British Journal of Clinical Pharmacology, vol. 84, no. 8, pp. 1806-1820. https://doi.org/10.1111/bcp.13615
  127. Weersink, RA, Bouma, M, Burger, DM, Drenth, JPH, Harkes-Idzinga, SF, Hunfeld, NGM, Metselaar, HJ, Monster-Simons, MH, Taxis, K & Borgsteede, SD 2018, 'Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis', Drug Safety, vol. 41, no. 6, pp. 603-613. https://doi.org/(...)07/s40264-017-0635-x
  128. Weldegiorgis M, de Zeeuw D, Li L, Parving HH, Hou FF, Remuzzi G, Greene T, Heerspink HJL. Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. Am J Kidney Dis. 2018 Jan;71(1):91-101.  doi: 10.1053/j.ajkd.2017.08.010. Epub 2017 Nov 16. PubMed PMID: 29153995.
  129. Wiedenmann T, Dietrich N, Fleming T, Altamura S, Deelman LE, Henning RH, Muckenthaler MU, Nawroth PP, Hammes HP, Wagner AH, Hecker M. Modulation of glutathione peroxidase activity by age-dependent carbonylation in glomeruli of diabetic mice. J Diabetes Complications. 2018 Feb;32(2):130-138. doi: 10.1016/j.jdiacomp.2017.11.007. Epub 2017 Nov 22. PubMed PMID: 29223856.
  130. Wildeboer A, du Pon E, Schuling J, Haaijer-Ruskamp FM, Denig P. Views of general practice staff about the use of a patient-oriented treatment decision aid in shared decision making for patients with type 2 diabetes: A mixed-methods study. Health Expect. 2018 Feb;21(1):64-74. doi: 10.1111/hex.12586. Epub 2017 Jun 21. PubMed PMID: 28636186; PubMed Central PMCID: PMC5750736.
  131. Wong MG, Heerspink HJL, Perkovic V. ACCORDION: Ensuring That We Hear the Music Clearly. Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1621-1623. doi: 10.2215/CJN.11370918. Epub 2018 Oct 25. PubMed PMID: 30361334.
  132. Wouthuyzen-Bakker M, Tornero E, Morata L, Nannan Panday PV, Jutte PC, Bori G, Kampinga GA, Soriano A. Moxifloxacin plus rifampin as an alternative for levofloxacin plus rifampin in the treatment of a prosthetic joint infection with  Staphylococcus aureus. Int J Antimicrob Agents. 2018 Jan;51(1):38-42. doi: 10.1016/j.ijantimicag.2017.04.011. Epub 2017 Jun 28. PubMed PMID: 28668678.
  133. Yamaki T, de Haas HJ, Tahara N, Petrov A, Mohar D, Haider N, Zhou J, Tahara A, Takeishi Y, Boersma HH, Scarabelli T, Kini A, Strauss HW, Narula J. Cardioprotection by minocycline in a rabbit model of ischemia/reperfusion injury: Detection of cell death by in vivo (111)In-GSAO SPECT. J Nucl Cardiol. 2018 Feb;25(1):94-100. doi: 10.1007/s12350-017-1031-8. Epub 2017 Aug 24. PubMed PMID: 28840574.
  134. Zhang D, Hu X, Li J, Hoogstra-Berends F, Zhuang Q, Esteban MA, de Groot N, Henning RH, Brundel BJJM. Converse role of class I and class IIa HDACs in the progression of atrial fibrillation. J Mol Cell Cardiol. 2018 Dec;125:39-49. doi: 10.1016/j.yjmcc.2018.09.010. Epub 2018 Oct 12. PubMed PMID: 30321539.
  135. Zuur MA, Ghimire S, Bolhuis MS, Wessels AMA, van Altena R, de Lange WCM, Kosterink JGW, Touw DJ, van der Werf TS, Akkerman OW, Alffenaar JWC. Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients. Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02250-17. doi: 10.1128/AAC.02250-17. Print 2018 May. PubMed PMID: 29439978; PubMed Central PMCID: PMC5923177.
  136. ​Zuur MA, van Asselt ADI, van 't Boveneind-Vrubleuskaya N, Aleksa A, Postma MJ, Alffenaar JWC. Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients. Int J Tuberc Lung Dis. 2018 Sep 1;22(9):991-999. doi: 10.5588/ijtld.17.0523. PubMed PMID: 30092863.